NCT02568280View on ClinicalTrials.gov

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 6, 2015

Primary Completion Date

April 25, 2016

Study Completion Date

April 25, 2016

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

Faster-acting insulin aspart

Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.

DRUG

insulin aspart

Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.

Trial Locations (1)

8010

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY